Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Gilead Sciences stock sits 2.32 percent below its yearly high

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Gilead Sciences reported second-quarter total product sales of $7.60 billion, representing an 8% year-over-year increase.

πŸ’Š HIV sales grew by 12% to reach $5.70 billion in the second quarter, reinforcing the core franchise's strength.

πŸ”¬ Oncology segment saw significant momentum with Trodelvy sales increasing 26% to $457 million.

πŸ’° The PrEP business exceeded $1 billion in quarterly sales, supported by a $4 billion annual run rate.

πŸ“Š Management raised full-year HIV sales growth guidance to 9-10%, up from the previous 8% estimate.

🎯 Total product sales guidance for the full year stands between $30.10 billion and $30.40 billion.

πŸ“… Third-quarter earnings are scheduled for release on October 29, 2026, after market close.

πŸ—£οΈ Management will host a webcast at 4:30 p.m. Eastern Time to discuss the upcoming results.

🏦 Analyst Truist Financial raised its price target to $158 on October 7, 2026.

πŸ“‰ The stock trades at EUR 139.49, which is 2.32% below its 52-week high of EUR 142.80.

Bullish Signals
  • Gilead Sciences achieved an 8% year-over-year increase in total product sales, reaching $7.60 billion in the second quarter.
  • HIV sales grew robustly by 12% to $5.70 billion, demonstrating continued strength in the company's primary revenue driver.
  • Oncology franchise Trodelvy delivered a strong 26% sales increase to $457 million, highlighting successful expansion in cancer therapy.
  • The PrEP business surpassed $1 billion in quarterly sales with a confirmed $4 billion annual run rate, indicating durable growth potential.
  • Management proactively raised full-year HIV sales growth guidance to 9-10%, signaling confidence in commercial execution.
  • Analyst Truist Financial increased its price target to $158, reflecting positive sentiment regarding the company's financial outlook.
Full Analysis
Gilead Sciences is preparing to report its third-quarter results on October 29, 2026, following a strong second quarter where total product sales reached $7.60 billion, an 8% year-over-year increase. The company's stock was trading at EUR 139.49 on October 19, 2026, sitting slightly below its 52-week high but well above its low. Key growth drivers highlighted include HIV sales, which rose 12% to $5.70 billion in the second quarter, and Trodelvy oncology sales, which surged 26% to $457 million. Additionally, the PrEP business exceeded $1 billion in quarterly sales, with management citing a $4 billion annual run rate for this franchise. Gilead has raised its full-year HIV sales growth guidance to a range of 9-10%, up from 8% previously, while maintaining total product sales guidance between $30.10 billion and $30.40 billion. Analyst Truist Financial recently raised its price target to $158, reflecting confidence in the company's commercial momentum across HIV, oncology, liver disease, and cell therapy segments.